Fact 5 of 8 in the story · Monday 2 November, 07h00
Dijon : les limites du remboursement des traitements anti-obésité
Après l'annonce du remboursement des traitements médicaux de l'obésité, professionnels et patients de Dijon font face à des critères d'IMC stricts et à des démarches complexes pour obtenir une prescription.
In brief
Health event (severity: low) in Dijon (Côte-d'Or), first detected on 2 November 2026 at 07:00. Reported by 1 source (1 article), last updated on 2 November 2026 at 07:00. Part of the story “Arrival of Wegovy in tablet form and tensions around anti-obesity treatments”.
- Category
- Health
- Severity
- Low
- Place
- 21 Côte-d'OrDijon
- Detected
- 2 Nov, 07h00
- Updated
- 2 Nov, 07h00
- Reference
- no.6772
What changed in the story at that point
1 article · 1 source · 1 bord sur 3 · outlets: left 0, centre 1, right 0
Story angles
This event does not yet have its own comparison: here is the story's Arrival of Wegovy in tablet form and tensions around anti-obesity treatments.
All three sides cover the arrival of Wegovy in tablet form, but the left emphasizes industrial competition and reimbursement conditions, the center develops waiting times, the parallel market and patient testimonies, while the right highlights the non-reimbursable nature and practical information (price, side effects).
Left
Highlights the rivalry between Novo Nordisk and Eli Lilly on a fast-growing global market, as well as the lack of reimbursement for the pills and the side effects to be aware of.
Centre
Develops the concrete consequences: waiting times of up to 18 months, the parallel market, the position of drug treatments compared with bariatric surgery and patient testimonies.
Right
Emphasizes the non-reimbursable nature of oral Wegovy and offers a practical format listing price, side effects and reimbursement.
Common points
- =Wegovy in tablet form is available in pharmacies in France from Monday 2 November.
- =The oral version is not reimbursed.
- =Wegovy had previously been administered by injection in France.
Divergences
- ≠The left focuses on competition between laboratories (Novo Nordisk, Eli Lilly), an angle little present on the right.
- ≠The center insists on waiting times of up to 18 months and the parallel market, absent from the left and right headlines provided.
- ≠The center and the right detail price and side effects in a practical format, while the left prioritizes the industrial and regulatory angle.
Written by an AI from headlines and extracts only of all events in the story · 2 Nov, 03h41
Lire les sources · 1 article, 1 source
- 07h00Le Bien PublicCentreAnalysis2 NovDijon. Traitement anti-obésité : « Ça ne doit pas devenir une baguette magique »
Passé l’annonce du remboursement des traitements médicaux de l’obésité, le temps de la frustration est arrivé assez vite. Calculs savants d’indices de masse corporelle, journées à remplir des dossiers et à pousser le peu de portes disponibles pour décrocher une prescription. Si tous les professionnels et associations se réjouissent de cette révolution, les premiers couacs apparaissent. En tête de liste, l’attente interminable pour de nombreux malades.
Further reading
Go up the thread
In the same story
- Les anti-obésité modifient les habitudes alimentaires des patients3 Nov
- Traitement anti-obésité en comprimé : des effets secondaires sur l'économie3 Nov
- Les douanes renforcent les contrôles face au trafic de coupe-faims comme le Wegovy3 Nov
- Wegovy tablet arrives in French pharmacies2 Nov
- Testimony from a patient treated with Mounjaro who lost 50 kg1 Nov
- Anti-obesity drugs: up to 18 months' wait for consultations1 Nov
Affected departments